StockData
Replimune Group, Inc. logo

Replimune Group, Inc. (REPL) stock

REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.41−0.48 (-2.19%)

Close on Nov 16, 2026Market cap $2.03BP/E –Yield –

Replimune net income

Net income is the profit left for shareholders after every expense, interest and tax.

Replimune's net income for the twelve months ending Sep 30, 2026 was -$271.03M. For fiscal 2026 it was -$313.94M. The highest annual figure on record is -$7.70M in fiscal 2017.

Annual net income

PeriodPeriod endValueChange
FY2026Mar 31, 2026-$313.94M–
FY2025Mar 31, 2025-$247.30M–
FY2024Mar 31, 2024-$215.79M–
FY2023Mar 31, 2023-$174.28M–
FY2022Mar 31, 2022-$118.04M–
FY2021Mar 31, 2021-$80.87M–
FY2020Mar 31, 2020-$52.63M–
FY2019Mar 31, 2019-$30.83M–
FY2018Mar 31, 2018-$19.70M–
FY2017Mar 31, 2017-$7.70M–

Quarterly net income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2027CQ3 2026Sep 30, 2026-$57.12M–
Q1 FY2027CQ2 2026Jun 30, 2026-$69.77M–
Q4 FY2026CQ1 2026Mar 31, 2026-$73.22M–
Q3 FY2026CQ4 2025Dec 31, 2025-$70.93M–
Q2 FY2026CQ3 2025Sep 30, 2025-$83.10M–
Q1 FY2026CQ2 2025Jun 30, 2025-$86.69M–
Q4 FY2025CQ1 2025Mar 31, 2025-$74.13M–
Q3 FY2025CQ4 2024Dec 31, 2024-$66.34M–
Q2 FY2025CQ3 2024Sep 30, 2024-$53.06M–
Q1 FY2025CQ2 2024Jun 30, 2024-$53.77M–
Q4 FY2024CQ1 2024Mar 31, 2024-$55.08M–
Q3 FY2024CQ4 2023Dec 31, 2023-$51.12M–
Q2 FY2024CQ3 2023Sep 30, 2023-$60.04M–
Q1 FY2024CQ2 2023Jun 30, 2023-$49.56M–
Q4 FY2023CQ1 2023Mar 31, 2023-$49.24M–
Q3 FY2023CQ4 2022Dec 31, 2022-$39.69M–
Q2 FY2023CQ3 2022Sep 30, 2022-$43.10M–
Q1 FY2023CQ2 2022Jun 30, 2022-$42.25M–
Q4 FY2022CQ1 2022Mar 31, 2022-$31.70M–
Q3 FY2022CQ4 2021Dec 31, 2021-$29.67M–
Q2 FY2022CQ3 2021Sep 30, 2021-$29.36M–
Q1 FY2022CQ2 2021Jun 30, 2021-$27.31M–
Q4 FY2021CQ1 2021Mar 31, 2021-$21.50M–
Q3 FY2021CQ4 2020Dec 31, 2020-$21.78M–
Q2 FY2021CQ3 2020Sep 30, 2020-$20.10M–
Q1 FY2021CQ2 2020Jun 30, 2020-$17.49M–
Q4 FY2020CQ1 2020Mar 31, 2020-$15.79M–
Q3 FY2020CQ4 2019Dec 31, 2019-$16.19M–
Q2 FY2020CQ3 2019Sep 30, 2019-$11.14M–
Q1 FY2020CQ2 2019Jun 30, 2019-$9.51M–
Q4 FY2019CQ1 2019Mar 31, 2019-$6.66M–
Q3 FY2019CQ4 2018Dec 31, 2018-$7.67M–
Q2 FY2019CQ3 2018Sep 30, 2018-$6.46M–
Q1 FY2019CQ2 2018Jun 30, 2018-$10.04M–
Q4 FY2018CQ1 2018Mar 31, 2018-$7.14M–
Q3 FY2018CQ4 2017Dec 31, 2017-$4.35M–
Q2 FY2018CQ3 2017Sep 30, 2017-$4.66M–
Q1 FY2018CQ2 2017Jun 30, 2017-$3.55M–

More Replimune figures

See a number that looks wrong?